-
Uncategorized4 months agoSTAT+: AI drug developer Insilico Medicine and Lilly ink commercialization deal worth up to $2.75 billion
Alex Zhavoronkov, CEO of Insilico Medicine, can’t stop complimenting Eli Lilly. “Lilly is better in AI than Insilico, and no other company is better in AI...
-
Uncategorized4 months ago
#ACC26: Merck leans toward lower Winrevair dose in Phase 3 trial for rare form of heart failure
#ACC26: Merck leans toward lower Winrevair dose in Phase 3 trial for rare form of heart failure
-
Uncategorized4 months ago
#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibody
#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibody
-
Uncategorized4 months ago
#AAD26: Tanabe’s Phase 3 win for drug targeting rare diseases that cause pain upon light exposure
Tanabe Pharma unveiled positive data from a Phase 3 trial of its oral drug for a pair of rare diseases, its first major clinical milestone after...
-
Uncategorized4 months agoOtsuka picks up PTSD drug with $700M Transcend buy
The buyout, which includes another $525 million in floated payouts, hands Otsuka a medicine it sees as a possibly “paradigm-shifting therapy” in psychiatry.
-
Uncategorized4 months agoThis week in Drug Discovery (23 – 27 March)
News round-up for 23 – 27 March February by Bruno Quinney, Content Team at DDW. This week, obesity could be treated in other ways than through drugs suppressing appetite. Elsewhere, prostate cancer...
-
Uncategorized4 months agoBeam reports positive data for genetic disease treatment
Biotechnology company Beam Therapeutics has reported encouraging data for its treatment for the genetic disease Alpha-1 Antitrypsin Deficiency (AATD). Beam announced BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation...
-
Uncategorized4 months agoFirst patient dosed in trial of Geographic Atrophy treatment
The first patient has been dosed in a first-in-human clinical trial of a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). CTx001, developed...
-
Uncategorized4 months agoMHRA to offer early review of non-animal data
The Medicines and Healthcare products Regulatory Agency (MHRA) will offer early review of non-animal data in a decision supporting the government’s strategy to reduce animal testing in...
-
Uncategorized4 months agoSygnature Discovery appoints new Head of In Vivo Pharmacology
CRO Sygnature Discovery has announced the appointment of Susanne Back as Head of In Vivo Pharmacology. Back has 20 years of in vivo pharmacology experience across academia and industry, including...
J&J pharma leader to retire; Krystal slumps on gene therapy miss
